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Abstract
The n-3 PUFA are a unique class of fatty acids that cannot be manufactured by the body, and must be acquired via dietary sources. In the
UK, as well as in other Western nations, these ‘essential’ fatty acids are consumed in quantities that fall below government guidelines. The
present study explored the effects of 12 weeks’ dietary supplementation with 1 g/d of two types of fish oil (FO; DHA-rich and EPA-rich) in
159 healthy young adults aged 18–35 years. An assessment of performance on a battery of computerised cognitive tasks and mood
measures took place before and following the 12-week treatment regimen. Venous blood samples were also supplied by participants at
both time points which were later analysed for serum fatty acid concentrations. Despite good adherence to the study protocol – as
reflected in increased concentrations of n-3 serum fatty acids – compared with placebo, the observed effects of both active treatments
were minimal. The only finding of note revealed that supplementation with EPA-rich FO may reduce subjective mental fatigue at times
of high cognitive demand, although further investigation is required. These findings, taken together with other recent reports of null
effects, suggest that dietary supplementation with n-3 PUFA in healthy, normally developing and impairment-free populations is unlikely
to result in cognitive enhancement.
Key words: Fish oil: n-3 PUFA: Cognitive function
The behavioural impact of consuming the n-3 PUFA DHA
and EPA in the diet has received a great deal of attention in
recent years. The effect of n-3 PUFA deficiency in animals
is well documented; an inadequate supply of dietary n-3
PUFA can result in a 50–80 % decline in brain DHA and is
associated with impaired learning and memory (reviewed in
Moriguchi & Salem(1)). Such data are not readily translated
into humans where equivalently low levels of n-3 PUFA are
rare. However, there is evidence to suggest that lower n-3
PUFA status (compared with controls and measured by
plasma/serum or erythrocyte concentrations) is a risk factor
for a plethora of adverse health outcomes including CVD(2),
inflammatory disease(3) and many neurodevelopmental and
psychiatric conditions such as attention deficit hyperactivity
disorder, dyslexia, depression, schizophrenia and dementia
(reviewed in Bourre(4)).
There is also some evidence to suggest that n-3 PUFA status
may be linked to cognitive function in healthy individuals. It is
well known that n-3 PUFA are essential for optimal fetal devel-
opment(5), and higher oily fish consumption in pregnancy is
associated with better developmental outcomes in children
at 4 years of age(6,7). In addition, a prospective epidemiologi-
cal study from Sweden revealed that incorporating fish
meals in the diet on a regular basis is associated with better
cognitive performance in adolescents (18 years) regardless
of socio-economic background(8). Further, epidemiological
studies(9–11) in older adults have suggested that increased
intake of n-3 PUFA is associated with a reduced risk of cogni-
tive decline. The consumption of n-3 PUFA is generally low in
nations following a typical ‘Western’ diet, and in the UK
specifically, consumption of oily fish, the predominant dietary
source of n-3 PUFA, is just a third of recommended levels(12).
Therefore, the investigation of the effects of increased intake
of n-3 PUFA on cognitive function is a logical avenue of
research to pursue. A number of intervention studies in both
children(13–17) and older adults(18,19) have addressed this
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Abbreviations: AA, arachidonic acid; CDB, cognitive demand battery; DASS, Depression, Anxiety and Stress Scale; FAME, fatty acid methyl ester; FO, fish oil;
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question with mixed results, but there are few available data
describing the effects of n-3 PUFA on cognitive function in
healthy younger adults (,50 years of age). Hamazaki
et al.(20) reported that 1·5–1·8 g/d DHA (from fish oil (FO))
for 3 months in forty-one healthy students prevented increases
in aggression towards others during times of mental stress
(university examinations), but did not engender performance
differences in comparison with the control group on the
Stroop or the dementia-detecting test adapted for this age
group. In two other studies, the effects of 4 weeks’ dietary
supplementation with 4 g FO on cognitive performance and
mood have been examined. Fontani et al.(21) reported that
participants administered FO achieved faster reaction times
on a Go/No-Go task and a Sustained Attention task, and
reported improved ratings of anger, anxiety, fatigue,
depression, confusion and vigour on the self-report Profile
of Mood States questionnaire compared with their pre-treat-
ment scores. However, in this study, no comparison was
made between the treatment and placebo groups. On the
other hand, Antypa et al.(22) found no effect of treatment on
any of the cognitive measures that they employed including
attention, memory, response inhibition and emotion recog-
nition; the only reported effect on mood was a small effect
on self-rated mental fatigue (Profile of Mood States).
From these studies, it is clear that any effects of n-3 PUFA
supplementation on behavioural outcomes in healthy young
adults remain to be adequately addressed. Animal studies
have suggested that the intervention period of both of the
latter studies would not be sufficient for adequate incorpor-
ation of the fatty acids to occur in certain tissues, including
the brain(23); therefore, the reported results may not reflect
the effects that might occur following a longer intervention
period. Further, a recurrent theme in the n-3 PUFA
supplementation literature, both in healthy and patient
populations, is the use of a wide range of treatment formulations
and doses. Both dietary DHA and EPA are known to influence
mechanisms that support cognitive function, but given the
evidence provided by the studies listed above, it is not possible
to identify the properties of an n-3 PUFA supplement, for
instance in terms of comparative levels of DHA or EPA, that
might have the greatest effect on cognitive performance.
Lastly, the previous intervention studies have either only
utilised a small number of tasks(20), focused on one cognitive
domain(21), or used tasks specifically involving emotional
information processing(22). In order to address these issues,
the present study assessed the effects of two different formu-
lations of FO in parallel, one with a higher ratio of EPA:DHA
and the other with a higher ratio of DHA:EPA, at doses consistent
with the current recommended daily intake of oily fish, across a
range of cognitive domains. The aim of the present investigation
was therefore to specifically evaluate the effects of 12 weeks’
supplementation of DHA-rich FO and EPA-rich FO dietary
supplements on cognitive function in healthy young adults
maintaining a regular diet containing oily fish not more than
once a week. Self-report mood assessments formed the
secondary part of the investigation.
Materials and methods
Participants
Volunteers were invited to participate if they declared that
they were in good health and that they were a non-smoker,
free from prescription, herbal, illicit or recreational drugs
(females taking the contraceptive pill were included), n-3 sup-
plements, that they were a native English speaker and eating
no more than one portion of oily fish a week on average
(less than or equal to four portions per month). All volunteers
were either students attending Northumbria University or
were university graduates living in Newcastle upon Tyne
and the surrounding area. As no previous research has pro-
vided adequate statistical information required for an accurate
power calculation, the treatment groups of fifty participants
were arrived at by considering the sample sizes employed in
intervention studies in adults with psychiatric disorders, the
literature regarding the cognitive effects of natural products
in similar cohorts and the resources available.
Of the 159 participants that were enrolled in the study, nine
participants did not attend the baseline session and eight
participants were excluded on the basis that their declared
average oily fish intake exceeded four portions per month.
Before the last day of the study (week 12), two participants
withdrew from the study. In both cases, the reasons were
unrelated to the intervention (glandular fever, moving home).
In addition, two participants had below 50 % compliance as
they had only taken 1 £ 500 mg capsule/d and were excluded
from the analysis at the blind data review point. The remain-
ing per-protocol sample consisted of 140 males and females;
their demographic details are presented in Table 1.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human participants were approved by the Northumbria
University School of Life Sciences Ethics Committee. Written
informed consent was obtained from all participants. This
trial was registered at clinicaltrials.gov: NCT01075919.
Table 1. Participants’ demographic information and baseline character-
istics*
(Mean values with their standard errors and number of subjects)
Placebo
DHA-rich
FO
EPA-rich
FO
Mean SEM Mean SEM Mean SEM
Male (n) 11 17 18
Female (n) 37 29 28
Age (years) 21·94 0·50 21·96 0·54 22·74 0·61
BMI (kg/m2) 24·83 0·81 24·11 0·51 23·89 0·61
Average portions of oily
fish consumed/month
1·35 0·20 1·85 0·20 1·20 0·20
Average portions of white
fish consumed/month
2·00 0·33 1·98 0·30 2·63 0·70
Breast-fed (n)
Yes 35 34 28
No 9 6 10
Unsure 2 8 8
FO, fish oil.
* P values are given for separate one-way ANOVA that were conducted on these
baseline data.
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Treatments
Before the start of the study, a restricted randomisation list
matching treatments to participant code numbers was compu-
ter generated. Participants were therefore randomly allocated
to one of three treatment groups: DHA-rich FO, EPA-rich FO
and placebo. The 1 g daily dose was provided by 2 £ 500 mg
capsules. The active capsules contained 497·5 mg of
deodorised FO plus 2·5 mg mixed tocopherols. The total
daily dose of n-3 PUFA for DHA-rich FO was 450 mg
DHA þ 90 mg EPA (5:1 DHA:EPA) and for EPA-rich FO, this
amount was 300 mg EPA þ 200 mg DHA (3:2 EPA:DHA) (It is
noted that the ratio of EPA:DHA in EPA-‘rich’ FO is closer to
1 compared with DHA-rich FO; however, in this case, EPA-
rich denotes containing more EPA than DHA). The total
daily dose for the placebo treatment was 1 g olive oil. The
ratios of DHA and EPA contained in the active treatments
are reflective of the extremes of the range that is found natu-
rally in fish; DHA-rich FO resembles that of yellowfin tuna and
herring, and some species of salmon have a similar ratio to
that present in EPA-rich FO. Treatment oils were purchased
from EPAX AS (Aalesund, Norway) and encapsulated by
Cardinal Health UK. All capsules used a brown bovine
gelatine casing and all treatments were packaged, labelled
and randomised on site by a disinterested third party.
Assessment of cognitive performance and mood
Performance was assessed using the Computerised Mental
Performance Assessment System, a software platform for the
presentation of classic and bespoke computerised cognitive
tasks. The cognitive tasks were presented in the same order
as outlined below (cognitive domain in brackets). All presen-
tations were made via a laptop computer with the exception
of the Word Recall and Verbal Fluency tasks, for which
participants used pen and paper to make their responses. All
reaction times were measured in milliseconds; accuracy
refers to the percentage of correct responses made.
Word Presentation. A unique set of fifteen words is pre-
sented. Words were selected at random from a large bank of
words derived from the Medical Research Council Psycholin-
guistic Database(24) matched for word length, frequency,
familiarity and concreteness. Stimulus duration was 1 s, as
was the inter-stimulus duration.
Immediate Word Recall (episodic memory). The partici-
pant was allowed 60 s to write down as many of the words
as possible. The task was scored for the number of correct
responses and number of errors.
Picture Presentation. A total of fifteen black-and-white
photographic images of objects and outdoor and indoor
scenes were presented sequentially on the screen for the par-
ticipant to remember at the rate of 1 every 3 s, with a stimulus
duration of 1 s. The same set of fifteen pictures was presented
to each participant in a random order. Participants were
informed that there would be a recognition task later in the
test session and therefore instructed to remember the details
in the pictures as they were presented.
Face Presentation. A set of twelve passport-style photo-
graphic images of people were presented sequentially in a
random order to participants. A first and last name was
assigned to each photograph and presented on the screen
underneath the person’s face. Stimulus duration was 1 s,
with a 3 s inter-stimulus duration. Participants were informed
that there would be a recognition task later in the test session
and therefore instructed to remember the faces and names
that were presented.
Simple Reaction Time (psychomotor speed/attention).
The participant was instructed to press the ‘space bar’ on
the laptop keyboard as quickly as possible every time an
upward pointing arrow appeared on the screen. A total of
fifty stimuli were presented with an inter-stimulus duration
that varied randomly between 1 and 3·5 s. Mean reaction
time was recorded.
Choice Reaction Time (attention/response inhibition). An
arrow appeared on the screen pointing to the left or to the
right. Participants responded with a left or right key press cor-
responding to the direction of the arrow. There was a ran-
domly varying inter-stimulus interval of between 1 and 3 s
for a total of fifty stimuli. Accuracy and mean reaction time
were recorded.
Four-Choice Reaction Time (attention). A visual represen-
tation of the four direction arrow keys of a standard keyboard
was presented on the screen. The arrows ‘lit up’ at random on
the screen until the corresponding key press was made. In all,
each arrow was the target stimulus twelve times, forming a
total of forty-eight stimuli for this task. Accuracy and mean
reaction time were recorded.
Stroop Task (attention/response inhibition). A compu-
terised version of the Stroop Task(25) was created. Words
describing colours (GREEN, BLUE, RED, YELLOW) were ran-
domly presented in incongruently coloured text (e.g. GREEN
was presented in blue text, etc.). For each of the fifty stimulus
presentations, participants were instructed to use the compu-
ter mouse and cursor to click the colour box located on the
right side of the screen that matched the colour of the text
the word was presented in. Accuracy and mean reaction
time were recorded.
Verbal Fluency (executive function/semantic memory).
Participants were presented with a letter on the screen and
were given 60 s to write down as many words as they could
beginning with that letter. The standard letters for this task –
F, A, S – were presented at baseline and C, M, T were pre-
sented at week 12, which were matched for beginning-of-
word frequency(26). An overall ‘Verbal Fluency’ score was
calculated by summing the number of permitted words
given in each of the three trials.
Numeric Working Memory (working memory). In this
task, five random digits from 1 to 9 were presented sequen-
tially for the participant to hold in memory. This was followed
by a series of thirty probe digits (fifteen targets and fifteen dis-
tractors) for each of which the participant indicated whether
or not it had been in the original series by a simple key
press. The task consisted of three separate trials. Accuracy
and mean reaction time were recorded.
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Alphabetic Working Memory (working memory). This
task was identical to Numeric Working Memory, the only
difference being that the stimuli were letters.
Corsi Blocks Task (spatial working memory). In this task,
nine identical blue squares appeared on the screen in
non-overlapping random positions. A set number of blocks
changed colour from blue to red in a randomly generated
sequence. The cursor was locked in position until the entire
sequence had been presented, at which point the participants
were instructed to repeat the sequence by clicking on the
blocks using the mouse and cursor. The task was repeated
five times at each level of difficulty. The sequence span
increased from four upwards, until the participant could
no longer correctly recall the sequence, resulting in a span
measure of non-verbal working memory, calculated by aver-
aging the level of the last five correctly completed trials.
Three-Back Task (working memory). A continuous string
of letters (upper and lower case; inter-stimulus interval of
2·5 s) was presented; forty-five letters in total with fifteen
target pairs. For each stimulus, participants were instructed to
indicate whether this was the same letter that appeared three
letters before. Accuracy and mean reaction time were recorded.
Telephone Number Working Memory Task (working
memory). A nine-digit ‘telephone number’ was presented on
the screen for 5 s which participants were instructed to hold in
their memory. After a delay of 10 s, participants had to input
the number using the numerical numbers at the top of the com-
puter keyboard. Participants scored correctly only if the entire
nine-digit number was entered exactly as the number that was
presented. There were eight trials in total. Accuracy and mean
total time taken to complete the trials were recorded.
Delayed Word Recall (episodic memory). The participant
was again given 60 s to write down as many of the words pre-
sented previously as possible. The total number of correct
responses was recorded.
Delayed Word Recognition (episodic memory). The orig-
inal fifteen words plus fifteen distractor words were presented
one at a time in a random order. For each word, the partici-
pant indicated whether or not it was included in the original
list of words by pressing appropriate ‘yes’ and ‘no’ keys as
quickly as possible. Stimuli remained on the screen until an
appropriate response had been made. Accuracy and mean
reaction time were recorded.
Delayed Picture Recognition (episodic memory). The
original fifteen pictures plus fifteen distractor pictures were
presented one at a time in a randomised order. For each
picture, participants indicated whether or not it was recog-
nised as being from the original series by pressing appropriate
‘yes’ and ‘no’ keys as quickly as possible. Stimuli remained on
the screen until an appropriate response had been made.
Accuracy and mean reaction time were recorded.
Names-to-Faces Recall (episodic memory). The twelve
original photographs presented at the outset were again pre-
sented on the screen, one at a time. Underneath each picture,
there was a list of four different first names and four different
last names. For each photograph, participants were instructed
to choose the first and last name that was originally presented
with the photograph. The number of correct responses for the
first and last names was recorded and collapsed to give an
overall score for this task.
Cognitive demand battery
The second half of the testing session comprised three rep-
etitions of a 10-min computerised ‘cognitive demand battery
(CDB)’. The battery has four components: serial 3 subtractions
(2 min), serial 7 subtractions (2 min), rapid visual information
processing (RVIP, 5 min) and a ‘mental fatigue’ visual analogue
scale. For the serial subtraction tasks, participants subtracted
either 3 or 7 consecutively from an original randomly gene-
rated number between 800 and 999 for the duration of the
task. The RVIP task required that participants respond with a
key press every time they detected three consecutive odd or
even numbers in a sequence of rapidly (100/min) presented
single digits (1–9). Previously, the battery has been effectively
used to investigate the effects of various nutritional inter-
ventions on cognitive and mental fatigue during periods of
sustained cognitive processing (see Reay et al.(27) for a full
description). For this study, data from the three repetitions
of the battery were averaged for each outcome from the
battery’s four-component tasks.
Assessment of mood
For the assessment of mood, two subjective ratings were
taken. A computerised version of the sixteen Bond–Lader
visual analogue scales was delivered before the CDB. The
results were combined to form three mood factors: ‘alert’,
‘calm’ and ‘content’(28). Participants also completed the
Depression, Anxiety and Stress Scales (DASS). This forty-
two-item self-report questionnaire requires participants to
rate how much each statement of negative emotional state
applied to them during the past week. This measure is
designed to assess both current state and change in state
over time (see Lovibond & Lovibond(29) for a full description).
Procedure
Participants attended the laboratory on three occasions (train-
ing day, baseline and week 12). Testing took place in a suite
of testing facilities, with participants visually isolated from
each other. The training day comprised the obtaining of
informed consent, training on the cognitive tasks and mood
questionnaires, collection of demographic data and collection
of a blood sample. No more than 8 d following the training
day, participants then attended the laboratory at 08.30 hours
in an overnight fasted state on the first day (baseline) and at
the end of the 12-week treatment regimen (week 12: average
time on treatment 86·71 (SD 4·97) d). On arrival at the baseline
session, participants were randomised to treatment group and
completed the full battery of Computerised Mental Perform-
ance Assessment System tasks, Bond–Lader visual analogue
scales, three repetitions of the CDB and filled in the DASS.
Participants’ blood pressure and heart rate were subsequently
recorded and at the end of the session, each participant
received their allocated capsules and were instructed to
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commence the treatment regimen that day. Participants from
whom a blood sample could not be obtained on the training
day were invited to attempt to give another sample at the
end of this session. The session at week 12 followed exactly
the same protocol as at the baseline session, with the excep-
tion that all unused capsules were collected before testing,
and at the very end of the session, participants were asked
to indicate which treatment they thought they had been
taking. The assessment schedule is presented in Fig. 1.
Blood samples
Participants were required to give two blood samples, the first
on either the training day (n 108) or at the end of the baseline
session (n 3) before supplementation and again at week 12
(n 99) after completing all the behavioural tasks. Blood
samples were collected by venepuncture into a serum gel
monovette (4·9 ml). The samples were immediately centri-
fuged at 3000 g for 10 min at 208C using an Allegra X-22
centrifuge (Beckman Coulter, High Wycombe, Bucks, UK).
The serum was decanted into a 1·5 ml microtube and immedi-
ately frozen at 2808C before analysis.
Methylation and extraction of the serum fatty acids was car-
ried out using a modified version of the method described by
Masood et al.(30). The procedure consisted of adding the
following components, in order, to a screw-top glass tube:
0·1 ml methyltricosanoate (internal standard; Fluka, Sigma-
Aldrich, Gillingham, Dorset, UK), 0·1 ml of blood serum
sample and 1·8 ml of an acetyl chloride–methanol mix (1:25,
prepared immediately before the start of the analysis; the
methanol contained 50 mg butylated hydroxytoluene/l to pre-
vent fatty acid oxidation). The mixture was swirled to mix and
then heated to 1008C for 60 min. After cooling, 2 ml of n-
hexane were added to the tube, vigorously mixed for 30 s
and the n-hexane layer, containing the derivatised fatty acid
methyl esters (FAME), was then transferred to a 2 ml micro-
reaction vessel (Supelco, Sigma-Aldrich, Gillingham, Dorset,
UK) using a Pasteur pipette. A further 1 ml of n-hexane
was added to the tube and the process was repeated. The
n-hexane in the vials was then evaporated to dryness under
a N2 flow at 408C, and the residue was resuspended in
0·1 ml n-hexane.
Analysis was carried out using a Thermo Scientific Focus gas
chromatograph fitted with a 30 m DB5 column (0·25 mm in
internal diameter) and a dual-stage quadrupole mass spectral
detector operating in the single-ion monitoring mode to maxi-
mise sensitivity (GC conditions were as follows: carrier gas,
He; flow rate, 1·5 ml/min; initial temperature, 1408C, hold for
5 min, ramp to 2808C at 48C/min, hold for 2 min). All com-
ponents had eluted by 35 min. The split ratio was 7:1 and
the injection port temperature 2708C. Individual FAME concen-
trations were calculated from the ratio of peak areas for the
component and the internal standard, corrected for the pre-
viously determined relative response factor of the component
and expressed as a weight percentage (i.e. mg per 100 mg)
of the total FAME concentration (excluding the internal
standard).
Serum fatty acid data are presented in Table 2.
Statistical methods
Data were analysed by one-way between-subject (treatment
group) ANCOVA, with data from the relevant outcome
measure at baseline as the covariate. A priori planned com-
parisons were made between placebo and both the active
treatments (DHA-rich FO and EPA-rich FO) utilising t tests
with the mean squares error from the ANCOVA as an error
term and adjusted means(31). To ensure the overall protection
level against type I errors, comparisons were strictly planned
before the commencement of the study and only those com-
parisons associated with a significant main effect on the omni-
bus ANCOVA were calculated. No correction was applied for
family-wise error rate as each separate analysis addressed a
specific experimental question made before testing. All testing
was two-tailed and all data were analysed using SPSS 16.0
(SPSS, Inc., Chicago, IL, USA).
Baseline characteristics
Results from separate between-group (treatment condition)
ANOVA using data collected on either the training day or base-
line session revealed no differences between participants in all
three treatment groups on age, BMI, oily fish consumption
Time (hours) Measure/assessment
Word presentation
Immediate word recall
Picture presentation
Face presentation
Simple reaction time
Choice reaction time
Four-choice reaction time
Stroop task
Numeric working memory
Alphabetic working memory
Corsi blocks task
3-Back task
Telephone number WM
Delayed word recall
Delayed word recongnition
Delayed picture recongnition
Names-to-faces recongnition
Bond–Lader VAS
08.30
DASS
Congnitive demand battery
3 × 10 min
Heart rate, BP
venous blood
09.00
09.25
09.15
Fig. 1. Baseline and week 12 assessment schedule. The pre-treatment
venous blood sample was collected on either the training day or at baseline.
Times are approximate. VAS, visual analogue scale; DASS, Depression,
Anxiety and Stress Scale; BP, blood pressure; WM, Working Memory.
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(see Table 1), and serum concentrations of DHA and EPA (see
Table 2). Additionally, no between-group differences were
detected on having been breast-fed, white fish consumption,
and any of the family background questionnaire items, with
the exception of the mother’s level of education. For this
item, the ANOVA revealed a significant main effect of treat-
ment group (F(2,137) ¼ 3·91, P¼0·022). Consequently, all of
the analyses were duplicated with the mother’s level of edu-
cation as a second covariate. However, the results from both
analyses were identical with regard to the main effects, so,
for brevity, the analysis including the mother’s level of edu-
cation is not reported.
Missing data
Data capture errors led to a reduced number of datasets for
the Corsi Blocks Task and two participants’ data were lost
from the entire CDB due to a fire drill during their baseline
testing session. During the data cleaning process (conducted
before treatment unblinding), a small number of instances
were identified and removed wherein the participant
had failed to follow the task instructions correctly
(e.g. by responding to a task with the incorrect button).
The subsequent reduced datasets for Stroop, serial 7 subtrac-
tions and RVIP tasks are indicated in Tables 3 and 4. For the
subsequent ANCOVA that were carried out on the outcomes
from these tasks, missing data were omitted using list-wise
deletion.
Results
Physiological data and compliance
Results for compliance as measured by capsule count were
similar in all three treatment conditions (91 % DHA-rich FO,
90 % EPA-rich FO and 92 % placebo). In addition, the results
of the paired-sample t tests shown in Table 2 reveal that
serum concentrations of DHA and EPA increased significantly
in both treatment groups but not in the placebo group,
indicating good adherence to the treatment regimen.
In a separate set of analyses, data from the serum samples
collected at week 12 were analysed by one-way ANCOVA,
with relevant serum data collected at baseline as the covariate
to investigate the presence of between-group differences on
serum PUFA following the intervention. A significant main
effect of treatment group was revealed for serum concen-
trations of both DHA and EPA (F(2,85) ¼ 18·10, P,0·001;
Table 2. Physiological measures by treatment group at baseline and week 12
(Mean values with their standard errors and number of subjects)
Baseline Week 12
n Mean SEM n Mean SEM
LA (n-6) Placebo 38 34·10 0·61 32 32·18*** 0·61
DHA-rich FO 37 34·23 0·059 34 31·80** 0·55
EPA-rich FO 38 34·00 0·68 33 32·26 0·69
AA (n-6) Placebo 38 7·64 0·32 32 8·51* 0·31
DHA-rich FO 37 7·65 0·35 34 7·49 0·28
EPA-rich FO 38 7·17 0·29 33 7·37 0·25
ALA (n-3) Placebo 36 0·19 0·02 29 0·19 0·02
DHA-rich FO 36 0·20 0·05 32 0·12** 0·01
EPA-rich FO 38 0·22 0·03 27 0·16* 0·02
DHA (n-3) Placebo 37 1·05 0·07 32 0·95 0·08
DHA-rich FO 37 1·26 0·09 34 1·87*** 0·11
EPA-rich FO 38 1·12 0·09 33 1·49* 0·11
EPA (n-3) Placebo 37 1·07 0·09 32 1·31 0·12
DHA-rich FO 37 1·05 0·06 34 1·36** 0·12
EPA-rich FO 38 1·16 0·09 33 1·78** 0·12
AA:DHA Placebo 38 8·19 0·49 32 10·64** 0·72
DHA-rich FO 37 6·94 0·52 34 4·46*** 0·30
EPA-rich FO 38 7·62 0·51 33 5·74** 0·43
AA:EPA Placebo 37 8·03 0·45 32 10·66*** 0·73
DHA-rich FO 37 7·74 0·39 34 4·46** 0·31
EPA-rich FO 38 6·96 0·42 33 7·74 0·43
SBP Placebo 48 113·00 1·61 48 114·71 1·86
DHA-rich FO 46 119·28 1·87 46 120·72 1·89
EPA-rich FO 46 117·30 1·64 46 116·80 1·91
DBP Placebo 48 62·98 1·62 48 64·88 1·37
DHA-rich FO 46 63·28 1·84 46 62·37 1·57
EPA-rich FO 46 61·37 1·46 46 63·50 1·43
Heart rate Placebo 48 77·08 2·28 48 75·04 1·14
DHA-rich FO 46 79·15 1·64 46 76·74 1·45
EPA-rich FO 46 77·28 2·00 46 77·96 1·24
LA, linoleic acid; FO, fish oil; AA, arachidonic acid; ALA, a-linolenic acid; SBP, systolic blood pressure;
DBP, diastolic blood pressure.
Mean values were significantly different from those of baseline concentrations: *P,0·05, **P,0·01,
***P,0·005 (paired-samples t test).
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Table 3. Cognitive task performance and mood outcomes by treatment group at baseline and week 12
(Mean values with their standard errors and number of subjects)
Baseline Week 12
n Mean SEM n Mean SEM F † P †
Immediate Word Recall (no. of correct responses) Placebo 48 6·99 0·36 48 7·79 0·36
DHA-rich FO 46 6·90 0·30 46 7·17 0·30 1·39 0·252
EPA-rich FO 46 7·33 0·33 46 7·59 0·31
Delayed Word Recall (no. of correct responses) Placebo 5·08 0·41 5·93 0·32
DHA-rich FO 4·71 0·37 5·61 0·35 0·05 0·949
EPA-rich FO 5·00 0·33 5·87 0·31
Simple RT Placebo 281·16 3·76 285·07 3·71
DHA-rich FO 289·56 5·20 288·52 5·14 0·13 0·880
EPA-rich FO 282·37 4·35 283·44 4·16
Choice RT Placebo 399·49 6·05 410·65 9·90
DHA-rich FO 403·15 8·51 399·59 8·21 1·02 0·365
EPA-rich FO 396·88 6·28 404·37 11·30
Choice RT (% accuracy) Placebo 94·88 0·53 95·71 0·47
DHA-rich FO 95·30 0·56 95·78 0·44 1·45 0·238
EPA-rich FO 94·65 0·65 94·70 0·55
Four-Choice RT Placebo 464·35 6·67 464·78 6·35
DHA-rich FO 482·41 10·66 470·22 9·72 1·20 0·310
EPA-rich FO 479·96 8·73 481·22 11·64
Four-choice RT (% accuracy) Placebo 99·05 0·21 99·18 0·18
DHA-rich FO 98·55 0·26 98·96 0·28 0·64 0·527
EPA-rich FO 98·69 0·34 98·69 0·32
Stroop (RT) Placebo 817·44 13·33 47 855·68 16·44
DHA-rich FO 45 858·44 20·43 44 845·02* 17·23 3·27 0·041
EPA-rich FO 843·00 17·21 863·87 20·64
Stroop (% accuracy) Placebo 99·38 0·16 99·40 0·16
DHA-rich FO 99·33 0·17 99·14 0·26 0·43 0·655
EPA-rich FO 99·00 0·27 99·26 0·18
Verbal Fluency Placebo 38·64 0·38 41·66 1·24
DHA-rich FO 39·70 0·44 41·21 1·46 1·46 0·236
EPA-rich FO 41·17 0·42 41·97 1·09
Numeric Working Memory (RT) Placebo 809·48 22·20 844·76 24·11
DHA-rich FO 829·36 24·40 877·76 26·92 0·61 0·545
EPA-rich FO 797·41 22·44 828·38 20·38
Numeric Working Memory (% accuracy) Placebo 96·09 0·64 96·85 0·42
DHA-rich FO 96·40 0·41 95·99 0·54 1·31 0·270
EPA-rich FO 95·53 0·61 95·36 0·87
Alphabetic Working Memory (RT) Placebo 466·10 12·66 479·76 12·86
DHA-rich FO 39 512·37 16·22 511·30 14·84 0·02 0·978
EPA-rich FO 459·46 13·59 472·33 13·65
Alphabetic Working Memory (% accuracy) Placebo 94·65 0·52 94·40 0·54
DHA-rich FO 94·28 0·56 94·52 0·69 0·05 0·949
EPA-rich FO 94·52 0·71 94·57 0·58
Corsi Blocks Span Placebo 6·01 0·16 5·99 0·17
DHA-rich FO 6·18 0·15 6·07 0·23 0·20 0·818
EPA-rich FO 5·64 0·21 5·81 0·25
Three-Back Task (RT) Placebo 45 1053·69 71·79 1020·13 78·79
DHA-rich FO 1146·98 98·39 1224·29 110·00 2·65 0·075
EPA-rich FO 37 1037·16 99·48 1196·88 111·93
Three-Back Task (% accuracy) Placebo 84·68 1·95 80·60 2·76
DHA-rich FO 81·52 2·63 82·83 2·36 1·96 0·145
EPA-rich FO 45 80·21 2·52 81·43 2·44
Telephone Number Task (RT) Placebo 5997·14 237·84 5758·90 204·10
DHA-rich FO 6578·48 259·07 6739·05 276·45 2·39 0·095
EPA-rich FO 6624·08 280·40 6588·26 297·23
Telephone Number Task (% accuracy) Placebo 35·42 3·87 35·16 3·99
DHA-rich FO 38·86 3·83 36·14 3·50 0·09 0·915
EPA-rich FO 38·59 3·80 37·77 3·82
Word Recognition (RT) Placebo 924·44 28·81 872·85 24·37
DHA-rich FO 892·43 21·04 894·11 24·64 2·72 0·070
EPA-rich FO 897·83 31·26 916·02 25·51
Word Recognition (% accuracy) Placebo 77·36 1·67 81·81 1·42
DHA-rich FO 75·36 1·46 79·35 1·53 0·42 0·659
EPA-rich FO 78·77 1·44 81·96 1·30
Picture Recognition (RT) Placebo 954·67 34·89 992·96 32·70
DHA-rich FO 972·35 57·54 1053·98 38·59 1·70 0·187
EPA-rich FO 933·63 29·59 1067·30 32·80
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F(2,84) ¼ 3·24, P¼0·044, respectively). Post hoc calculations
(Bonferroni) revealed that participants in the DHA-rich FO
group had higher serum DHA than those in the placebo
(P,0·001) and EPA-rich FO groups (P¼0·022). The partici-
pants in the EPA-rich FO group also had higher serum DHA
than those in the placebo group (P¼0·004). Interestingly,
with regard to serum EPA concentrations, post hoc calculations
did not reveal any significant differences between either treat-
ment group and placebo.
The same analysis was applied to the arachidonic acid
(AA):EPA ratio data and a significant main effect of group
was also detected (F(2,84) ¼ 33·61, P,0·001). The ratio of
AA:EPA was higher in the placebo group than in both the
DHA-rich FO (P,0·001) and EPA-rich FO (P,0·001) groups.
Table 3. Continued
Baseline Week 12
n Mean SEM n Mean SEM F † P †
Picture Recognition (% accuracy) Placebo 88·40 1·47 83·40 1·65
DHA-rich FO 89·42 1·29 86·16 1·58 0·64 0·529
EPA-rich FO 91·96 0·79 87·17 1·40
Names-to-Faces Recall (no. of correct responses) Placebo 11·21 0·69 13·90 0·73
DHA-rich FO 11·98 0·62 12·67* 0·60 3·73 0·026
EPA-rich FO 12·07 0·55 12·26* 0·68
Bond–Lader alert Placebo 49·78 2·05 53·62 2·15
DHA-rich FO 50·59 1·76 52·47 2·12 0·14 0·871
EPA-rich FO 48·28 1·82 52·46 2·21
Bond–Lader calm Placebo 59·68 1·62 62·58 1·82
DHA-rich FO 58·05 1·88 60·64 1·77 0·12 0·901
EPA-rich FO 57·02 1·76 60·23 2·09
Bond–Lader content Placebo 59·40 1·68 61·07 1·74
DHA-rich FO 57·87 1·86 61·98 1·74 0·39 0·680
EPA-rich FO 58·73 1·58 60·65 1·97
DASS-stress Placebo 9·27 0·98 7·92 0·96
DHA-rich FO 7·74 0·85 7·98 0·93 0·52 0·595
EPA-rich FO 8·07 1·01 7·24 0·93
DASS-anxiety Placebo 3·42 0·62 3·38 0·64
DHA-rich FO 3·54 0·56 3·24 0·50 0·21 0·808
EPA-rich FO 2·65 0·56 3·09 0·60
DASS-depression Placebo 4·63 0·76 3·27 0·82
DHA-rich FO 5·54 0·94 4·52 0·82 0·40 0·672
EPA-rich FO 4·41 0·79 3·67 0·65
FO, fish oil; RT, reaction time; DASS, Depression, Anxiety and Stress Scale.
* Mean value was significantly different from that of the placebo treatment (P,0·05).
† From the primary ANCOVA.
Table 4. Outcome measures on the cognitive demand battery by treatment group at baseline and week 12
(Mean values with their standard errors and number of subjects)
Baseline Week 12
n Mean SEM n Mean SEM F† P†
Serial 3 subtractions (no. of correct responses) Placebo 47 38·05 2·09 47 37·55 2·01
DHA-rich FO 45 35·86 2·02 45 35·51 1·97 0·08 0·925
EPA-rich FO 46 36·12 1·90 46 35·53 1·76
Serial 7 subtractions (no. of correct responses) Placebo 48 21·49 1·51 46 21·40 1·48
DHA-rich FO 44 21·11 1·46 45 20·99 1·55 0·15 0·863
EPA-rich FO 46 20·61 1·39 46 20·99 1·31
RVIP (RT) Placebo 47 484·87 9·20 44 485·64 10·23
DHA-rich FO 44 492·03 8·51 41 481·37 8·99 0·12 0·897
EPA-rich FO 42 473·61 7·14 43 475·46 9·53
RVIP (% accuracy) Placebo 47 50·83 3·30 44 50·31 3·69
DHA-rich FO 44 49·50 3·45 41 51·68 3·34 1·48 0·232
EPA-rich FO 42 53·40 3·26 43 55·33 3·73
RVIP (false alarms) Placebo 47 8·14 1·63 44 8·55 1·59
DHA-rich FO 44 6·58 1·04 41 6·76 1·04 0·35 0·705
EPA-rich FO 42 8·50 1·63 43 10·36 2·38
Mental fatigue (/100) Placebo 48 66·75 2·32 47 68·78 2·02
DHA-rich FO 46 61·67 2·16 46 65·35 2·54 4·36 0·015
EPA-rich FO 46 63·93 2·29 45 59·36** 2·67
FO, fish oil; RVIP, rapid visual information processing; RT, reaction time.
** Mean value was significantly different from that of the placebo treatment (P,0·01).
† From the primary ANCOVA.
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There was no significant difference between the active treat-
ment groups on the ratio of AA:EPA.
At the end of the week 12 session, participants were asked
to say if they thought they had been taking FO or placebo
capsules; participants were just as likely to give the correct
answer in the EPA-rich FO treatment group (49 %) as those
taking placebo (66 %) (x 2 (1) ¼ 0·08, P¼0·109), whereas
those in the DHA-rich FO group were less likely (37 %) to
give the correct answer (x 2 (1) ¼ 0·003, P¼0·006).
With regard to the other physiological measures that were
taken, there was no evidence of an effect of treatment on
either blood pressure or heart rate. These data are also
presented in Table 2.
Cognitive performance battery (Computerised Mental
Performance Assessment System)
There was evidence of a significant main effect of treatment
on two of the outcome measures: reaction time on the
Stroop Task (F(2,133) ¼ 3·27, P¼0·041) and the number of
correctly matched items on the Names-to-Faces Task
(F(2,136) ¼ 3·73, P¼0·026). Planned comparisons revealed
that participants in the DHA-rich FO group were faster on
the Stroop Task compared with placebo (t(133) ¼ 2·50,
P¼0·014, r 0·26) but participants in both the DHA-rich and
EPA-rich FO groups matched fewer items on the Names-
to-Faces Task (t(136) ¼ 2·00, P¼0·047, r 0·21; t(136) ¼ 2·52,
P¼0·013, r 0·26, respectively). Performance data collected at
baseline and week 12 for every outcome can be found in
Table 3.
Cognitive demand battery
Performance data collected at baseline and week 12 on the
CDB can be found in Table 4.
There was no evidence of a main effect of treatment on
any of the cognitive performance measures from the CBD.
However, a main effect of treatment was detected for self-
reported mental fatigue during the CDB (F(2,134) ¼ 4·36,
P¼0·015). Planned comparisons revealed that mental fatigue
scores for participants in the EPA-rich FO group were signi-
ficantly lower compared with placebo (t(134) ¼ 22·67,
P¼0·009, r 0·27).
Mood
There was no effect of treatment on either the Bond–Lader
visual analogue scales or the DASS. The scores from both
these measures can be found at the bottom of Table 3.
Discussion
In the present study, the effects of 12 weeks’ supplementation
with DHA-rich and EPA-rich FO in a sample of healthy adults
who were recruited simply on the basis of not consuming a
high amount of oily fish (less than or equal to one portion
of oily fish a week on average) were explored. Given the
number of different tasks, along with the small number of
significant outcomes that were detected and the bidirectional
nature of the results, these findings do not provide any solid
evidence of cognitive or mood (Bond–Lader, DASS) enhance-
ment following supplementation with FO at a dose that is
roughly equivalent to the current UK recommendation(32).
Based on these findings, one possible interpretation could
be that even though three-quarters of the present sample
reported consuming less oily fish than the current recommen-
dation, and despite the fact that serum concentrations of DHA
and EPA were similarly low(22) or even slightly lower than
those that have been observed in normal healthy participants
in previous studies(33,34), endogenous n-3 PUFA levels may
not have been below the level that would predispose the par-
ticipants to performance deficits, and render supplementation
effective or necessary. In particular, one study in animals does
support the idea of a threshold of n-3 PUFA intake (and sub-
sequent cellular incorporation), below which performance is
adversely affected. Jensen et al.(35) compared the effects of
four different diets on brain phospholipids and performance
on the Morris Water Maze task in rats following four gener-
ations of breeding, adhering to the dietary interventions.
These authors have reported that when brain levels of n-3
PUFA (DHA þ docosapentaenoic acid) fell to 22 % (placebo),
performance on the Morris Water Maze task was worse, with
significantly longer escape latencies compared with rats fed
vegetable and marine oils, in which levels of n-3 PUFA were
24 and 27 %, respectively. Although a similar threshold has
yet to be established in humans, one study conducted in
undernourished children reported beneficial effects of a FO
intervention(16), compared with those in well-nourished chil-
dren, which have reported no effect of treatment on cognitive
or other performance outcomes(13,14,17), despite evidence of
improved fatty acid profiles following the intervention(14,17).
Another possibility is that, apart from having a lower intake
of n-3 PUFA, another important factor when considering the
effects of n-3 PUFA supplementation in otherwise healthy
samples is the presence of performance decrements at the
outset. For example, two recent publications described the
effects of n-3 PUFA supplementation in healthy older adults
who were not suffering from cognitive impairment or demen-
tia. A key difference between these studies was that in one
study, participants were selected on the basis of self-reported
memory complaint and identified as having age-related
cognitive decline(19), as opposed to the other study, in which
participants were not suffering from any decline(18). Although
the intervention period was longer for the latter study (24
months), no effects of the treatment were observed, compared
with improvements on a measure of learning and episodic
memory (Paired-Associate Learning task) in the sample suffer-
ing cognitive decline after 6 months’ supplementation in the
study reported by Yurko-Mauro et al.(19). Similarly, an interest-
ing secondary analysis of the data presented by Dalton et al.(16)
revealed that the effects of a DHA-rich fish flour spread given
to schoolchildren for 6 months were more pronounced in
children whose baseline performance scores were lower(36),
again suggesting that any effects of n-3 PUFA supplementation
in healthy unimpaired samples might only be observed
when performance is below average to begin with. This may
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certainly explain the recent string of null results from this and
other studies that have investigated the effects of added n-3
PUFA in healthy participants, even when these samples are
not consuming the recommended levels of oily fish(13–15,17,18).
A final possibility is that the dose of n-3 PUFA provided by
the active treatments (DHA-rich FO: 450 mg DHA þ 90 mg
EPA; EPA-rich FO: 300 mg EPA þ 200 mg DHA) was too low
for an effect to be observed, or alternatively that the interven-
tion period was too short. However, reports from similar inter-
vention trials in healthy adults that have administered higher
doses of n-3 PUFA over a longer period than the present
study have also yielded null results(18,22,33). Therefore, overall,
it must be concluded at present that the available data do not
provide any evidence that supplementation can enhance
cognitive function in healthy populations. This is not to say
that n-3 PUFA have no effect on overall brain function despite
the absence of performance benefits. Data from our own
laboratory(37) and McNamara et al.(38) reveal that changes in
the functional activation of areas of the brain following sup-
plementation over short periods (8–12 weeks) are not necess-
arily accompanied by simultaneous changes on performance
measures. It is possible that such functional changes, i.e.
increased activation and cerebral blood flow, could help
explain the epidemiological data that show a positive associ-
ation between fish consumption and cognitive function(6–11).
Naturally, these hypotheses require further investigation and
comprise a number of potential future lines of investigation.
In the present study, one significant finding that may merit
further discussion is the beneficial effect of EPA-rich FO on
self-reported mental fatigue during 30 min of cognitively
demanding tasks. Previous reports have found reduced ratings
of mental fatigue on the Profile of Mood States following FO
supplementation for 4 weeks in healthy adults(21,22). Further,
it is known that increased intake of EPA modulates the
production of pro-inflammatory AA-derived eicosanoids(39)
and, at least at the epidemiological level, increased levels of
pro-inflammatory cytokines are positively associated with
tiredness(40), suggesting that a reduced AA:EPA ratio may be
particularly relevant in times of high cognitive demand.
However, it is notable that reduced mental fatigue was not
observed in the DHA-rich FO treatment group where the
serum AA:EPA ratio was also significantly lower than that
of the placebo group. Future research could investigate
the relationship between self-reported mental fatigue and
these biomarkers, or evaluate the efficacy of EPA-rich FO for
alleviation of symptoms of mental and physical fatigue, in
populations who subjectively report fatigue, such as indivi-
duals in full-time work, primary caretakers of children and
carers, for example.
With regard to the physiological effects of the treatments,
both DHA-rich and EPA-rich FO were effective at significantly
increasing serum DHA (450 and 200 mg, respectively) over
placebo. In contrast, there was no significant difference in
serum EPA between placebo and either treatment group at
week 12, which may be rectified in future studies by providing
a higher dose of EPA. The observed changes in fatty acid con-
centrations in the placebo group may be a consequence of
measuring serum fatty acids, reflective only of dietary intake
in the prior 4 weeks, as opposed to whole blood analysis
which provides information on intake in the previous 3–4
months. With regard to the other physiological measures,
there was no evidence of an effect of either of the active
treatments on heart rate or blood pressure. This latter finding
is in agreement with a meta-analysis reported by Morris &
Sacks(41) who found no effect of n-3 PUFA supplements on
blood pressure in healthy adults.
A strength of the present study was the full assessment of
cognitive function that was employed. The combination of
numerous outcome measures analysed using a powerful (i.e.
least conservative) statistical approach that resulted in the
detection of only a limited number of significant results
suggests that a type II error has not been committed. It must
also be noted that if corrections for multiple testing had
been applied, these results would disappear. Therefore, as
no coherent pattern of either positive or negative effects of
either active treatment was detected, it can be confidently
concluded that the behavioural effects of FO supplements
on healthy young adults are minimal. These results are
comparable with those reported in normally developing
children(13–17) and older adults free from cognitive impair-
ment(18). Equivalent findings have also been reported in
animal studies which show that rats raised on a balanced
and n-3-adequate diet but who are not given any additional
n-3 PUFA perform no worse on behavioural tests than animals
given the additional n-3 PUFA(42). It may be that very long
periods of supplementation (2 þ years) are necessary to
show any effects of treatment, which are unfortunately
much less feasible to investigate in human studies.
Conclusions
The present study describes a novel investigation where the
effects of DHA-rich and EPA-rich FO on cognitive function
and mood were investigated in parallel in comparison with
placebo. The primary aim of the present study was to assess
the effects of n-3 PUFA supplementation in a population
where few data are available regarding cognitive performance
and mood. A 1 g dose of FO was chosen so that the results
could be readily translated into meaningful dietary advice.
As such, the data presented here do not favour the use of
FO supplements for cognitive or mood enhancement. The
results from the present and similar studies in healthy indivi-
duals suggest that simply giving more n-3 PUFA does not
necessarily result in improved performance, and that the
relationship between dietary intake of n-3 PUFA and their
effect on the brain, and consequently cognitive function, is
far more complex than originally thought. While the results
here could not be taken as an encouragement for further
investigations of the direct effect of n-3 PUFA supplementation
on cognitive function, the use of neuroimaging techniques,
even in the absence of behavioural modification, may well
be useful in delineating the effects that n-3 PUFA are exerting
on overall brain function and physiology. Further, it is prob-
able that ongoing research into the interaction between n-3
PUFA intake and genes such as those for lipid desaturase
(SCD-1, FADS1 and FADS2; stearoyl–CoA desaturase, and
Fish oil supplementation in healthy adults 1241
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
fatty acid desaturase 1 and 2, respectively) or the APOE-e4
allele, for example, will be able to address some of the
issues relating to individual differences in the propensity to
develop diseases associated with low n-3 PUFA intake. It is
evident that dietary n-3 PUFA are important, yet understand-
ing exactly how and why will be the objective of many
future investigations.
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